Ilyang PharmaceuticalLtd Balance Sheet Health
Financial Health criteria checks 4/6
Ilyang PharmaceuticalLtd has a total shareholder equity of ₩271.4B and total debt of ₩121.7B, which brings its debt-to-equity ratio to 44.8%. Its total assets and total liabilities are ₩533.6B and ₩262.2B respectively. Ilyang PharmaceuticalLtd's EBIT is ₩20.6B making its interest coverage ratio 7.6. It has cash and short-term investments of ₩26.9B.
Key information
44.8%
Debt to equity ratio
₩121.68b
Debt
| Interest coverage ratio | 7.6x |
| Cash | ₩26.86b |
| Equity | ₩271.37b |
| Total liabilities | ₩262.25b |
| Total assets | ₩533.61b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: A007575's short term assets (₩206.1B) do not cover its short term liabilities (₩230.5B).
Long Term Liabilities: A007575's short term assets (₩206.1B) exceed its long term liabilities (₩31.8B).
Debt to Equity History and Analysis
Debt Level: A007575's net debt to equity ratio (34.9%) is considered satisfactory.
Reducing Debt: A007575's debt to equity ratio has reduced from 61.9% to 44.8% over the past 5 years.
Debt Coverage: A007575's debt is not well covered by operating cash flow (1.9%).
Interest Coverage: A007575's interest payments on its debt are well covered by EBIT (7.6x coverage).